Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2927635

Fc1cc(Cc2ccc(Cl)cc2)ccc1CN1CCCC1.N

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
ALDH1A1 P00352 4/20 0.54
HTT P42858 1/20 0.53
CXCR3 P49682 5/20 0.49
CCR5 P51681 1/20 0.48
LTA4H P09960 2/20 0.46
KMT2A Q03164 1/20 0.45
CACNB4 O00305 1/20 0.43
CACNA1A O00555 1/20 0.43
CACNA1G O43497 1/20 0.43
CACNG3 O60359 1/20 0.43
CACNA1F O60840 1/20 0.43
CACNA1H O95180 1/20 0.43
CACNB3 P54284 1/20 0.43
CACNA2D1 P54289 1/20 0.43
CACNG7 P62955 1/20 0.43
CACNA1B Q00975 1/20 0.43
CACNA1D Q01668 1/20 0.43
CACNB1 Q02641 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31010076 0.82 KDM4E (0.70) KDM4ESMN1; SMN2ALDH1A1HTTCXCR3
SCHEMBL2927634 0.81 CHRM1 (0.51) KDM4ESMN1; SMN2ALDH1A1HTTCXCR3
Ammonia Solution, Strong SCHEMBL2924519 0.81 ALDH1A1 (0.81) KDM4ESMN1; SMN2ALDH1A1LTA4HHRH3
Hydrochloric Acid SCHEMBL23850500 0.79 CXCR3 (0.65) KDM4ESMN1; SMN2ALDH1A1CXCR3POLB
SCHEMBL1934178 0.77 KDM4E (0.63) KDM4ESMN1; SMN2ALDH1A1HTTCXCR3
SCHEMBL20210279 0.77 KDM4E (0.63) KDM4ESMN1; SMN2ALDH1A1HTTCXCR3
SCHEMBL2236823 0.77 NCF1 (0.61) KDM4ESMN1; SMN2ALDH1A1HTTCXCR3
SCHEMBL2927630 0.75 KDM4E (0.52) KDM4ESMN1; SMN2ALDH1A1HTTCXCR3
SCHEMBL2933281 0.75 KDM4E (0.52) KDM4ESMN1; SMN2ALDH1A1CXCR3KMT2A
SCHEMBL19634064 0.75 ALDH1A1 (0.58) KDM4ESMN1; SMN2ALDH1A1HTTCXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121616-B1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2010-09-15 EP disclosed
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS GIUSEPPE CAMPIANI (IT) 2010-04-15 US disclosed
EP-2121616-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS Campiani, Giuseppe (IT) 2009-11-25 EP disclosed
WO-2008101891-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS QTRT1, QTRT2, IL4I1 KDM4E 315/4885SMN1; SMN2 4673/4885ALDH1A1 4027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.